Abstract:The purposes of this study were to investigate the effects of B cell translocation gene 2 (BTG2) on the proliferation, apoptosis, and invasion of triple-negative breast cancer and to provide an experimental basis for the future treatment of human triple-negative breast cancer. A pcDNA3.1-BTG2 eukaryotic expression vector was constructed and transfected into the MDA-MB-231 human triple-negative breast cancer cell line using lipofection. Then, relevant changes in the biological characteristics of the BTG2-expressing cell line were analyzed using MTT (tetrazolium blue), flow cytometry, and Transwell invasion chamber assays. Additionally, the effects of BTG2 expression on cyclin D1, caspase 3, and matrix metalloproteinases 1/2 (MMP-1/-2) expression were analyzed. Cell proliferation was significantly lower in the pcDNA3.1-BTG2-transfected group compared to the empty vector and blank control groups (p < 0.05). There was no significant difference between the empty vector and blank control groups. FCM results demonstrated that there were significantly more cells in the G1 phase of the cell cycle and fewer S phase cells in the pcDNA3.1-BTG2 group than in the empty vector and blank control groups (p < 0.05). Additionally, the proportion of cells that migrated across the membrane was significantly lower in the pcDNA3.1-BTG2 group than in the empty vector and blank control groups (p < 0.05). Cyclin D1 and MMP-1/-2 expression were significantly lower in MDA-MB-231 cells transfected with pcDNA3.1-BTG2 as compared to the empty vector and blank control groups (p < 0.05). Caspase 3 expression was significantly higher in MDA-MB-231 cells from the pcDNA3.1-BTG2 group compared to the empty vector and blank control groups (p < 0.05). In conclusion, BTG2 may inhibit MDA-MB-231 proliferation and promote apoptosis. Additionally, BTG2 may also inhibit the invasion of MDA-MB-231 human triple-negative breast cancer cells.

A Recombined Fusion Protein Ptd-Grb2-Sh2 Inhibits The Proliferation Of Breast Cancer Cells In Vitro

Recombinant Fusion Proteins FPTD-Grb2-SH2 and FPTD-Grb2-SH2M Inhibit the Proliferation of Breast Cancer Cells in Vitro.

Efficient P53 Activation and Apoptosis Induction of MDM2/MDMX Inhibitory Protein, a Recombinant Cell-Permeable Fusion Protein, in P53- Breast Cancer Cells.

Optimization strategies for expression of a novel bifunctional anti-PD-L1/TGFBR2-ECD fusion protein.

Selective Cytotoxicity to HER2-Positive Tumor Cells by a Recombinant E23sfv-Td-tbid Protein Containing a Furin Cleavage Sequence

A Novel Recombinant Fusion Protein with Soluble PD-1 and TIM-3 Domains Effectively Binds to Cancer Cells

[Targeted Tumor Suppression by a Secreted Fusion Protein Consisting of Anti- Erbb2 Antibody and Reversed Caspase-3 to SKBr3 Cells].

HER2-targeting Recombinant Protein with Truncated Pseudomonas Exotoxin: A Translocation Domain Efficiently Kills Breast Cancer Cells

Fusion protein containing SH3 domain of c-Abl induces hepatocarcinoma cells to apoptosis

Construction and characterization of a recombinant human beta defensin 2 fusion protein targeting the epidermal growth factor receptor: in vitro study

Synergistic tumor growth-inhibitory effect of the prostate-specific antigen-activated fusion peptide BSD352 for prostate cancer therapy

The Generation of Dual-Targeting Fusion Protein PD-L1/CD47 for the Inhibition of Triple-Negative Breast Cancer

Fusion protein for treating breast cancer and application thereof

BTG2 Inhibits the Proliferation, Invasion, and Apoptosis of MDA-MB-231 Triple-Negative Breast Cancer Cells

Inhibition of Cell Proliferation, Migration and Invasion by A Glioma-Targeted Fusion Protein Combining the P53 C Terminus and Mdm2-Binding Domain

Fusion of apoptosis‐related protein Cytochrome c with anti‐HER‐2 single‐chain antibody targets the suppression of HER‐2+ breast cancer

[Construction, Expression and Cell Growth Inhibition of Translocating Peptide/granzyme B Fusion Protein Gene].

Peptide Inhibitor Targeting the Extraterminal Domain in BRD4 Potently Suppresses Breast Cancer Both In Vitro and In Vivo

[Growth Inhibitory Effects of Recombinant Granzyme B Containing Different N-terminal Translocating Peptides].

Breast cancer targeted/ therapeutic with double and triple fusion Immunotoxins

Secreted Antibody/granzyme B Fusion Protein Stimulates Selective Killing of HER2-overexpressing Tumor Cells.